On Wednesday, there are stocks with unusual volume. Let's take a look.
By Mill Chart
Last update: Apr 17, 2024
Let's have a look at the stocks with an unusual volume in today's session.
Today's unusual volume stocks
| Ticker | Change | Comment |
|---|---|---|
| DYNT | 8.71% | So far 750.29K shares of DYNATRONICS CORP (NASDAQ:DYNT) have traded in today's session. Investors in NASDAQ:DYNT are enjoying a price surge of 8.71% today, indicating bullish market sentiment. This is 40.45% above the average daily volume of the last 50 days. |
| SXTC | -23.52% | 1.84M shares of CHINA SXT PHARMACEUTICALS IN (NASDAQ:SXTC) exchanged hands today. Leading to a price decrease of 23.52%. In comparison to the average daily volume of the last 50 days, the current volume is 48.77% above. This suggests a notable change in trading activity. |
| PALI | 10.62% | So far 1.4M shares of PALISADE BIO INC (NASDAQ:PALI) have traded in today's session. The share price increased by 10.62%. Compared to the average daily volume of the past 50 days, the current volume is 74.17% above, suggesting an unusual level of trading activity. |
| OMQS | 3.59% | The trading volume of OMNIQ CORP (NASDAQ:OMQS) today is 1.29M shares, which is considered unusual. Shares in NASDAQ:OMQS are on the rise, with a gain of 3.59% observed in today's trading session. With an average daily volume of 435.66K over the past 50 days, today's volume is 197.0% above the average, indicating a potential shift in market sentiment. |
| RCON | -7.83% | 945.32K shares of RECON TECHNOLOGY LTD-CLASS A (NASDAQ:RCON) exchanged hands today. Leading to a price decrease of 7.83%. With an average daily volume of 775.08K over the past 50 days, today's volume is 21.96% above the average, indicating a potential shift in market sentiment. |
| MRNS | 16.25% | So far 5.06M shares of MARINUS PHARMACEUTICALS INC (NASDAQ:MRNS) have traded in today's session. Shares in NASDAQ:MRNS are on the rise, with a gain of 16.25% observed in today's trading session. The average daily volume over the past 50 days is 1.61M. Hence, the current volume is 214.0% above the average volume, indicating a deviation from the usual trading pattern. |
| ICCM | -1.54% | So far 1.15M shares of ICECURE MEDICAL LTD (NASDAQ:ICCM) have traded in today's session. This decline in share price leads to a decrease of 1.54%. This volume is 109.0% above the average 50 day volume. |
| GL | 4.81% | GLOBE LIFE INC (NYSE:GL) has an unusual volume of 2.95M shares today. The share price of NYSE:GL increased by 4.81% today, reflecting positive market movement. The average volume over the last 50 days is 2.34M, making today's volume 26.16% above the average. This signifies a notable change in market participation. Two days ago the company had a press release: Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Globe Life, Inc. (GL). |
| MCBC | 0.22% | MACATAWA BANK CORP (NASDAQ:MCBC) has an unusual volume of 305.61K shares today. The market is favoring NASDAQ:MCBC today, as its share price records a notable increase of 0.22%. The average volume measured over 50 days is 113.63K, so this is 169.0% above the average volume. A press release (BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)) was released yesterday. |
| ENLV | -2.07% | 324.85K shares of ENLIVEX THERAPEUTICS LTD (NASDAQ:ENLV) have been traded so far today. The share price has dropped by 2.07% in today's session. Today's trading volume is 70.23% above the average 50-day volume, indicating a significant deviation from the norm. A press release (Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis) was released yesterday. |
To see the full list of unusual volume stocks you can use our unusual volume stocks screener.
ENLIVEX THERAPEUTICS LTD
NASDAQ:ENLV (4/26/2024, 7:00:02 PM)
1.44
-0.01 (-0.69%)
ENLV News
6 days ago - Enlivex Therapeutics LtdEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
11 days ago - ChartmillOn Wednesday, there are stocks with unusual volume. Let's take a look.Let's have a look at the stocks with an unusual volume in today's session.
13 days ago - Enlivex Therapeutics LtdEnlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisNes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory approval for this trial from the Israeli Ministry of Health (IMOH) in January.
13 days ago - ChartmillWhich stocks are experiencing notable movement on Monday?Which stocks are moving on Monday?
16 days ago - ChartmillThese stocks are moving in today's sessionFriday's session: top gainers and losers
17 days ago - Enlivex Therapeutics LtdEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisNes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...
17 days ago - Enlivex Therapeutics LtdEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisAnalysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety...
24 days ago - InvestorPlaceENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023ENLV stock results show that Enlivex Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
24 days ago - BusinessInsiderENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023InvestorPlace - Stock Market News, Stock Advice & Trading Tips Enlivex Therapeutics (NASDAQ:ENLV) just reported results for the fourth quarter...
